Aardvark Therapeutics Inc... (AARD)
Aardvark Therapeutics Common Stock Statistics
Share Statistics
Aardvark Therapeutics Common Stock has 21.7M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 21.7M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 900 |
| FTD / Avg. Volume | 0.53% |
Short Selling Information
The latest short interest is 467.12K, so 2.18% of the outstanding shares have been sold short.
| Short Interest | 467.12K |
| Short % of Shares Out | 2.18% |
| Short % of Float | 3.67% |
| Short Ratio (days to cover) | 3.62 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Aardvark Therapeutics Common Stock's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aardvark Therapeutics Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.05, with a Debt / Equity ratio of -0.01.
| Current Ratio | 15.05 |
| Quick Ratio | 15.05 |
| Debt / Equity | -0.01 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-935.82K |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Aardvark Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | null |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 49.86 |
| Average Volume (20 Days) | 169.52K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -22.79M |
| Net Income | -20.59M |
| EBITDA | -22.65M |
| EBIT | -22.67M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 61.64M in cash and 779K in debt, giving a net cash position of 60.86M.
| Cash & Cash Equivalents | 61.64M |
| Total Debt | 779K |
| Net Cash | 60.86M |
| Retained Earnings | -58.33M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -18.09M and capital expenditures -109K, giving a free cash flow of -18.2M.
| Operating Cash Flow | -18.09M |
| Capital Expenditures | -109K |
| Free Cash Flow | -18.2M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AARD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AARD is $26, which is 205.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $26 |
| Price Target Difference | 205.9% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |